Biotech News

Ocugen to Participate in Upcoming November Investor and Industry Conferences

Ocugen (OCGN)Ocugen2026-10-29 11:02 ESTCompany update

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in November 2026.

Related news

OCGNOcugen2026-09-29 11:02 EST

Ocugen to Participate in Upcoming October Investor and Industry Conferences

OCGNOcugen2026-09-30 11:02 EST

Ocugen to Participate in Upcoming Scientific Conferences

OCULOcular Therapeutix2026-10-29 11:00 EST

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

TARSTarsus Pharmaceuticals2026-11-05 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

MXCTMaxCyte2026-10-28 12:06 EST

MaxCyte to Participate in Three Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-09-03 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

PRQRProQR Therapeutics2026-09-02 12:00 EST

ProQR to Participate in Upcoming Investor Conferences in September 2026

EDITEditas Medicine2026-09-01 13:00 EST

Editas Medicine to Participate in Upcoming Investor Conferences

BLTEBelite Bio2026-09-01 12:00 EST

Belite Bio to Participate in Four Upcoming Investor Conferences

OCULOcular Therapeutix2026-10-01 11:00 EST

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

View all latest news

Ocugen

Gene Therapies for Retinal Disease Ocugen develops one-time gene therapies for inherited and acquired causes of blindness. Its lead ophthalmology programs are designed to address broad patient populations rather than only individuals with a single disease-causing mutation. Modifier Gene Therapy Platform The platform delivers master...

Recent company news

OCGNOcugen2026-10-29 11:02 EST

Ocugen to Participate in Upcoming November Investor and Industry Conferences

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

OCGNOcugen2026-10-14 10:30 EST

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

OCGNOcugen2026-10-06 11:02 EST

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

OCGNOcugen2026-09-30 11:02 EST

Ocugen to Participate in Upcoming Scientific Conferences

Stock data

Close: 0.82 USD
Market cap: 453.62M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States